Skip to main content
Top
Published in: Journal of Gastroenterology 5/2010

01-05-2010 | Original Article—Liver, Pancreas, and Biliary Tract

Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells

Authors: Yuki Nishimura-Sakurai, Naoya Sakamoto, Kaoru Mogushi, Satoshi Nagaie, Mina Nakagawa, Yasuhiro Itsui, Megumi Tasaka-Fujita, Yuko Onuki-Karakama, Goki Suda, Kako Mishima, Machi Yamamoto, Mayumi Ueyama, Yusuke Funaoka, Takako Watanabe, Seishin Azuma, Yuko Sekine-Osajima, Sei Kakinuma, Kiichiro Tsuchiya, Nobuyuki Enomoto, Hiroshi Tanaka, Mamoru Watanabe

Published in: Journal of Gastroenterology | Issue 5/2010

Login to get access

Abstract

Background

Hepatitis C virus (HCV) replication is affected by several host factors. Here, we screened host genes and molecular pathways that are involved in HCV replication by comprehensive analyses using two genotypes of HCV replicon-expressing cells, their cured cells and naïve Huh7 cells.

Methods

Huh7 cell lines that stably expressed HCV genotype 1b or 2a replicon were used. The cured cells were established by treating HCV replicon cells with interferon-alpha. Expression of 54,675 cellular genes was analyzed by GeneChip DNA microarray. The data were analyzed by using the KEGG Pathway database.

Results

Hierarchical clustering analysis showed that the gene-expression profiles of each cell group constituted clear clusters of naïve, HCV replicon-expressed, and cured cell lines. The pathway process analysis between the replicon-expressing and the cured cell lines identified significantly altered pathways, including MAPK, steroid biosynthesis and TGF-beta signaling pathways, suggesting that these pathways were affected directly by HCV replication. Comparison of cured and naïve Huh7 cells identified pathways, including steroid biosynthesis and sphingolipid metabolism, suggesting that these pathways were required for efficient HCV replication. Cytoplasmic lipid droplets were obviously increased in replicon-expressing and cured cells as compared to naïve cells. HCV replication was significantly suppressed by peroxisome proliferator-activated receptor (PPAR)-alpha agonists but augmented by PPAR-gamma agonists.

Conclusion

Comprehensive gene expression and pathway analyses show that lipid biosynthesis pathways are crucial to support proficient virus replication. These metabolic pathways could constitute novel antiviral targets against HCV.
Appendix
Available only for authorised users
Literature
2.
go back to reference Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.PubMed Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–55.PubMed
3.
go back to reference Sakamoto N, Watanabe M. New therapeutic approaches to hepatitis C virus. J Gastroenterol. 2009;44:643–9.CrossRefPubMed Sakamoto N, Watanabe M. New therapeutic approaches to hepatitis C virus. J Gastroenterol. 2009;44:643–9.CrossRefPubMed
4.
go back to reference Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–3.CrossRefPubMed Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science. 1999;285:110–3.CrossRefPubMed
5.
go back to reference Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791–6.CrossRefPubMed Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005;11:791–6.CrossRefPubMed
6.
go back to reference Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA. 2005;102:9294–9.CrossRefPubMed Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA. 2005;102:9294–9.CrossRefPubMed
7.
go back to reference Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe. 2009;5:298–307.CrossRefPubMed Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe. 2009;5:298–307.CrossRefPubMed
8.
go back to reference Itsui Y, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Koyama T, et al. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat. 2006;13:690–700.CrossRefPubMed Itsui Y, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Koyama T, et al. Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. J Viral Hepat. 2006;13:690–700.CrossRefPubMed
9.
go back to reference Yamashiro T, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Nakagawa M, et al. Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. J Gastroenterol. 2006;41:750–7.CrossRefPubMed Yamashiro T, Sakamoto N, Kurosaki M, Kanazawa N, Tanabe Y, Nakagawa M, et al. Negative regulation of intracellular hepatitis C virus replication by interferon regulatory factor 3. J Gastroenterol. 2006;41:750–7.CrossRefPubMed
10.
go back to reference Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA. 2005;102:2986–91.CrossRefPubMed Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA. 2005;102:2986–91.CrossRefPubMed
11.
go back to reference Sakamoto N, Yoshimura M, Kimura T, Toyama K, Sekine-Osajima Y, Watanabe M, et al. Bone morphogenetic protein-7 and interferon-alpha synergistically suppress hepatitis C virus replicon. Biochem Biophys Res Commun. 2007;357:467–73.CrossRefPubMed Sakamoto N, Yoshimura M, Kimura T, Toyama K, Sekine-Osajima Y, Watanabe M, et al. Bone morphogenetic protein-7 and interferon-alpha synergistically suppress hepatitis C virus replicon. Biochem Biophys Res Commun. 2007;357:467–73.CrossRefPubMed
12.
go back to reference Murata T, Ohshima T, Yamaji M, Hosaka M, Miyanari Y, Hijikata M, et al. Suppression of hepatitis C virus replicon by TGF-beta. Virology. 2005;331:407–17.CrossRefPubMed Murata T, Ohshima T, Yamaji M, Hosaka M, Miyanari Y, Hijikata M, et al. Suppression of hepatitis C virus replicon by TGF-beta. Virology. 2005;331:407–17.CrossRefPubMed
13.
go back to reference Shimakami T, Honda M, Kusakawa T, Murata T, Shimotohno K, Kaneko S, et al. Effect of hepatitis C virus (HCV) NS5B-nucleolin interaction on HCV replication with HCV subgenomic replicon. J Virol. 2006;80:3332–40.CrossRefPubMed Shimakami T, Honda M, Kusakawa T, Murata T, Shimotohno K, Kaneko S, et al. Effect of hepatitis C virus (HCV) NS5B-nucleolin interaction on HCV replication with HCV subgenomic replicon. J Virol. 2006;80:3332–40.CrossRefPubMed
14.
go back to reference Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005;129:1031–41.CrossRefPubMed Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005;129:1031–41.CrossRefPubMed
15.
go back to reference Tardif KD, Mori K, Siddiqui A. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol. 2002;76:7453–9.CrossRefPubMed Tardif KD, Mori K, Siddiqui A. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol. 2002;76:7453–9.CrossRefPubMed
16.
go back to reference Wang J, Tong W, Zhang X, Chen L, Yi Z, Pan T, et al. Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. FEBS Lett. 2006;580:4392–400.CrossRefPubMed Wang J, Tong W, Zhang X, Chen L, Yi Z, Pan T, et al. Hepatitis C virus non-structural protein NS5A interacts with FKBP38 and inhibits apoptosis in Huh7 hepatoma cells. FEBS Lett. 2006;580:4392–400.CrossRefPubMed
17.
go back to reference Choi YW, Tan YJ, Lim SG, Hong W, Goh PY. Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. Biochem Biophys Res Commun. 2004;318:514–9.CrossRefPubMed Choi YW, Tan YJ, Lim SG, Hong W, Goh PY. Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. Biochem Biophys Res Commun. 2004;318:514–9.CrossRefPubMed
18.
go back to reference Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, et al. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J. 2006;25:5015–25.CrossRefPubMed Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, et al. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J. 2006;25:5015–25.CrossRefPubMed
19.
go back to reference Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A, et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol. 2005;1:333–7.CrossRefPubMed Sakamoto H, Okamoto K, Aoki M, Kato H, Katsume A, Ohta A, et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol. 2005;1:333–7.CrossRefPubMed
20.
go back to reference Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003;4:602–8.CrossRefPubMed Yokota T, Sakamoto N, Enomoto N, Tanabe Y, Miyagishi M, Maekawa S, et al. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 2003;4:602–8.CrossRefPubMed
21.
go back to reference Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis. 2004;189:1129–39.CrossRefPubMed Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis. 2004;189:1129–39.CrossRefPubMed
22.
go back to reference Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol. 2001;75:8516–23.CrossRefPubMed Guo JT, Bichko VV, Seeger C. Effect of alpha interferon on the hepatitis C virus replicon. J Virol. 2001;75:8516–23.CrossRefPubMed
23.
go back to reference Donnelly MLL, Hughes LE, Luke G, Mendoza H, ten Dam E, Gani D, et al. The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol. 2001;82:1027–41.PubMed Donnelly MLL, Hughes LE, Luke G, Mendoza H, ten Dam E, Gani D, et al. The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol. 2001;82:1027–41.PubMed
24.
go back to reference Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun. 2004;313:42–7.CrossRefPubMed Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun. 2004;313:42–7.CrossRefPubMed
25.
go back to reference Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76:13001–14.CrossRefPubMed Blight KJ, McKeating JA, Rice CM. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol. 2002;76:13001–14.CrossRefPubMed
26.
go back to reference Strand C, Enell J, Hedenfalk I, Ferno M. RNA quality in frozen breast cancer samples and the influence on gene expression analysis—a comparison of three evaluation methods using microcapillary electrophoresis traces. BMC Mol Biol. 2007;8:38.CrossRefPubMed Strand C, Enell J, Hedenfalk I, Ferno M. RNA quality in frozen breast cancer samples and the influence on gene expression analysis—a comparison of three evaluation methods using microcapillary electrophoresis traces. BMC Mol Biol. 2007;8:38.CrossRefPubMed
27.
go back to reference Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116–21.CrossRefPubMed Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116–21.CrossRefPubMed
28.
go back to reference Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008;36:D480–4.CrossRefPubMed Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, Itoh M, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008;36:D480–4.CrossRefPubMed
29.
go back to reference Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289–300. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289–300.
30.
go back to reference Ciccaglione AR, Marcantonio C, Tritarelli E, Tataseo P, Ferraris A, Bruni R, et al. Microarray analysis identifies a common set of cellular genes modulated by different HCV replicon clones. BMC Genomics. 2008;9:309.CrossRefPubMed Ciccaglione AR, Marcantonio C, Tritarelli E, Tataseo P, Ferraris A, Bruni R, et al. Microarray analysis identifies a common set of cellular genes modulated by different HCV replicon clones. BMC Genomics. 2008;9:309.CrossRefPubMed
31.
go back to reference Hayashi J, Stoyanova R, Seeger C. The transcriptome of HCV replicon expressing cell lines in the presence of alpha interferon. Virology. 2005;335:264–75.CrossRefPubMed Hayashi J, Stoyanova R, Seeger C. The transcriptome of HCV replicon expressing cell lines in the presence of alpha interferon. Virology. 2005;335:264–75.CrossRefPubMed
32.
go back to reference Scholle F, Li K, Bodola F, Ikeda M, Luxon BA, Lemon SM. Virus–host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis. J Virol. 2004;78:1513–24.CrossRefPubMed Scholle F, Li K, Bodola F, Ikeda M, Luxon BA, Lemon SM. Virus–host cell interactions during hepatitis C virus RNA replication: impact of polyprotein expression on the cellular transcriptome and cell cycle association with viral RNA synthesis. J Virol. 2004;78:1513–24.CrossRefPubMed
33.
go back to reference Abe K, Ikeda M, Dansako H, Naka K, Shimotohno K, Kato N. cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells. Virus Res. 2005;107:73–81.CrossRefPubMed Abe K, Ikeda M, Dansako H, Naka K, Shimotohno K, Kato N. cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells. Virus Res. 2005;107:73–81.CrossRefPubMed
34.
go back to reference Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, Nishimura-Sakurai Y, et al. Development of plaque assays for hepatitis C virus and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology. 2008;371:71–85.CrossRefPubMed Sekine-Osajima Y, Sakamoto N, Nakagawa M, Itsui Y, Tasaka M, Nishimura-Sakurai Y, et al. Development of plaque assays for hepatitis C virus and isolation of mutants with enhanced cytopathogenicity and replication capacity. Virology. 2008;371:71–85.CrossRefPubMed
35.
go back to reference Mottola G, Cardinali G, Ceccacci A, Trozzi C, Bartholomew L, Torrisi MR, et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology. 2002;293:31–43.CrossRefPubMed Mottola G, Cardinali G, Ceccacci A, Trozzi C, Bartholomew L, Torrisi MR, et al. Hepatitis C virus nonstructural proteins are localized in a modified endoplasmic reticulum of cells expressing viral subgenomic replicons. Virology. 2002;293:31–43.CrossRefPubMed
36.
go back to reference Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol. 2003;77:5487–92.CrossRefPubMed Gosert R, Egger D, Lohmann V, Bartenschlager R, Blum HE, Bienz K, et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J Virol. 2003;77:5487–92.CrossRefPubMed
37.
go back to reference Amemiya F, Maekawa S, Itakura Y, Kanayama A, Takano S, Yamaguchi T, et al. Targeting lipid metabolism in the treatment of hepatitis C. J Infect Dis. 2008;197:361–70.CrossRefPubMed Amemiya F, Maekawa S, Itakura Y, Kanayama A, Takano S, Yamaguchi T, et al. Targeting lipid metabolism in the treatment of hepatitis C. J Infect Dis. 2008;197:361–70.CrossRefPubMed
38.
go back to reference Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44:117–25.CrossRefPubMed Ikeda M, Abe K, Yamada M, Dansako H, Naka K, Kato N. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006;44:117–25.CrossRefPubMed
39.
go back to reference Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, Kato N, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology. 2007;132:311–20.CrossRefPubMed Kim SS, Peng LF, Lin W, Choe WH, Sakamoto N, Kato N, et al. A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication. Gastroenterology. 2007;132:311–20.CrossRefPubMed
40.
go back to reference Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol. 2008;103:1383–9.CrossRefPubMed Bader T, Fazili J, Madhoun M, Aston C, Hughes D, Rizvi S, et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol. 2008;103:1383–9.CrossRefPubMed
41.
go back to reference Yang W, Hood BL, Chadwick SL, Liu S, Watkins SC, Luo G, et al. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology. 2008;48:1396–403.CrossRefPubMed Yang W, Hood BL, Chadwick SL, Liu S, Watkins SC, Luo G, et al. Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production. Hepatology. 2008;48:1396–403.CrossRefPubMed
42.
go back to reference Li Y, Tharappel JC, Gooper S, Glenn M, Glauert HP, Spear BT. Expression of the hydrogen peroxide-generating enzyme fatty acyl CoA oxidase activates NF-kappaB. DNA Cell Biol. 2000;19:113–20.CrossRefPubMed Li Y, Tharappel JC, Gooper S, Glenn M, Glauert HP, Spear BT. Expression of the hydrogen peroxide-generating enzyme fatty acyl CoA oxidase activates NF-kappaB. DNA Cell Biol. 2000;19:113–20.CrossRefPubMed
43.
go back to reference Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998;273:29577–85.CrossRefPubMed Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem. 1998;273:29577–85.CrossRefPubMed
44.
go back to reference Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489–98.CrossRefPubMed Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest. 1999;103:1489–98.CrossRefPubMed
45.
go back to reference Schiefelbein D, Seitz O, Goren I, Dissmann JP, Schmidt H, Bachmann M, et al. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair. Mol Pharmacol. 2008;74:952–63.CrossRefPubMed Schiefelbein D, Seitz O, Goren I, Dissmann JP, Schmidt H, Bachmann M, et al. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair. Mol Pharmacol. 2008;74:952–63.CrossRefPubMed
46.
go back to reference Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett. 2009;583:2720–6.CrossRefPubMed Kim K, Kim KH, Ha E, Park JY, Sakamoto N, Cheong J. Hepatitis C virus NS5A protein increases hepatic lipid accumulation via induction of activation and expression of PPARgamma. FEBS Lett. 2009;583:2720–6.CrossRefPubMed
47.
go back to reference Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology. 2003;125:1808–17.CrossRefPubMed Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology. 2003;125:1808–17.CrossRefPubMed
Metadata
Title
Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells
Authors
Yuki Nishimura-Sakurai
Naoya Sakamoto
Kaoru Mogushi
Satoshi Nagaie
Mina Nakagawa
Yasuhiro Itsui
Megumi Tasaka-Fujita
Yuko Onuki-Karakama
Goki Suda
Kako Mishima
Machi Yamamoto
Mayumi Ueyama
Yusuke Funaoka
Takako Watanabe
Seishin Azuma
Yuko Sekine-Osajima
Sei Kakinuma
Kiichiro Tsuchiya
Nobuyuki Enomoto
Hiroshi Tanaka
Mamoru Watanabe
Publication date
01-05-2010
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 5/2010
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0162-3

Other articles of this Issue 5/2010

Journal of Gastroenterology 5/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.